HCP Touchpoint Intelligence
Where SM patients are seen across the diagnostic journey, who orders what, and which HCPs miss the most opportunities.
Cohort size
2,000
Specialties touched
10
Unique HCPs (rendering)
240
Specialist touchpoints before correct diagnosis
Patients seen by each specialty along the pre-diagnosis pathway. Click a bar to drill in.
Specialty metrics
Diagnostic behaviour, biomarker ordering, referral, and treatment initiation by specialty
| Specialty | Patients seen | % cohort | Avg days pre-dx | Dx actions | Tryptase % | KIT D816V % | Heme referral % | Tx init % | Missed opp. |
|---|---|---|---|---|---|---|---|---|---|
| Primary care | 1,418 | 70.9% | 68 | 284 | 48% | 48% | 84% | 61% | 0 |
| Emergency medicine | 1,786 | 89.3% | 102 | 357 | 47% | 47% | 84% | 62% | 0 |
| Allergy/Immunology | 1,623 | 81.2% | 133 | 1136 | 49% | 49% | 85% | 63% | 26 |
| Dermatology | 1,489 | 74.5% | 157 | 1042 | 47% | 47% | 84% | 62% | 27 |
| Gastroenterology | 382 | 19.1% | 372 | 267 | 42% | 42% | 38% | 26% | 45 |
| Rheumatology | 933 | 46.7% | 191 | 653 | 46% | 46% | 85% | 64% | 28 |
| Hematology/Oncology | 1,715 | 85.8% | 144 | 1201 | 49% | 49% | 98% | 72% | 22 |
| Pathology | 1,360 | 68% | 213 | 952 | 69% | 69% | 92% | 69% | 10 |
| Nuclear medicine / imaging | 1,410 | 70.5% | 283 | 282 | 50% | 50% | 85% | 64% | 0 |
| Pharmacy | 1,514 | 75.7% | 271 | 303 | 49% | 49% | 92% | 82% | 0 |
HCP rankings
Top 15 HCPs by suspected SM volume - sortable across diagnostic, referral, and treatment behaviour
| HCP ID | Specialty | Suspected SM volume | Tryptase % | KIT D816V % | Heme referral % | Avg dx delay | Progression detection % | Tx init % |
|---|---|---|---|---|---|---|---|---|
| H1060 | Allergy/Immunology | 16 | 44% | 31% | 100% | 237d | 25% | 75% |
| H1150 | Rheumatology | 15 | 60% | 47% | 80% | 327d | 40% | 67% |
| H1069 | Primary care | 15 | 53% | 53% | 87% | 342d | 40% | 60% |
| H1185 | Hematology/Oncology | 14 | 57% | 57% | 57% | 496d | 43% | 50% |
| H1161 | Emergency medicine | 14 | 50% | 36% | 86% | 302d | 29% | 57% |
| H1212 | Primary care | 14 | 36% | 29% | 64% | 480d | 43% | 43% |
| H1106 | Hematology/Oncology | 14 | 29% | 29% | 79% | 361d | 36% | 57% |
| H1126 | Dermatology | 14 | 50% | 36% | 93% | 266d | 29% | 79% |
| H1190 | Primary care | 13 | 62% | 46% | 85% | 344d | 15% | 69% |
| H1218 | Emergency medicine | 13 | 31% | 31% | 62% | 496d | 31% | 38% |
| H1202 | Primary care | 13 | 38% | 31% | 85% | 312d | 15% | 46% |
| H1201 | Dermatology | 13 | 46% | 38% | 100% | 237d | 38% | 69% |
| H1030 | Hematology/Oncology | 13 | 46% | 38% | 77% | 358d | 38% | 54% |
| H1194 | Allergy/Immunology | 13 | 62% | 54% | 77% | 340d | 31% | 69% |
| H1231 | Hematology/Oncology | 13 | 54% | 31% | 77% | 397d | 15% | 54% |